BR112013025761A2 - inibidores de hsp90 - Google Patents

inibidores de hsp90

Info

Publication number
BR112013025761A2
BR112013025761A2 BR112013025761A BR112013025761A BR112013025761A2 BR 112013025761 A2 BR112013025761 A2 BR 112013025761A2 BR 112013025761 A BR112013025761 A BR 112013025761A BR 112013025761 A BR112013025761 A BR 112013025761A BR 112013025761 A2 BR112013025761 A2 BR 112013025761A2
Authority
BR
Brazil
Prior art keywords
hsp90 inhibitors
hsp90
inhibitors
Prior art date
Application number
BR112013025761A
Other languages
English (en)
Inventor
Chiosis Gabriela
Taldone Tony
Original Assignee
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer Res filed Critical Sloan Kettering Inst Cancer Res
Publication of BR112013025761A2 publication Critical patent/BR112013025761A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013025761A 2011-04-05 2012-04-05 inibidores de hsp90 BR112013025761A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
PCT/US2012/032373 WO2012138896A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Publications (1)

Publication Number Publication Date
BR112013025761A2 true BR112013025761A2 (pt) 2018-05-29

Family

ID=46018086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025761A BR112013025761A2 (pt) 2011-04-05 2012-04-05 inibidores de hsp90

Country Status (12)

Country Link
US (2) US9546170B2 (pt)
EP (1) EP2694506B1 (pt)
JP (1) JP5961683B2 (pt)
KR (1) KR101984480B1 (pt)
CN (1) CN103596955B (pt)
AU (1) AU2012240079B2 (pt)
BR (1) BR112013025761A2 (pt)
CA (1) CA2832099C (pt)
EA (1) EA024647B1 (pt)
ES (1) ES2647889T3 (pt)
MX (1) MX354215B (pt)
WO (1) WO2012138896A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
KR101906568B1 (ko) 2009-10-07 2018-10-10 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 저해제로서 유용한 퓨린 유도체
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US20140294725A1 (en) 2011-07-08 2014-10-02 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
PL2812341T3 (pl) 2012-02-09 2020-03-31 The University Of Kansas Inhibitory C-końcowe HSP90
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 grp94 저해제 및 이의 용도
KR102325454B1 (ko) 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
BR112017005313A2 (pt) 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
AU2016336351A1 (en) 2015-10-05 2018-05-10 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
IL278698B2 (en) 2018-05-14 2024-06-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Her族チロシンキナーゼの分解および/または阻害方法および組成物
AU2877102A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Small molecule compositions for binding to hsp90
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
JP4397691B2 (ja) 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
CA2477344A1 (en) 2002-02-28 2003-09-04 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2456000T3 (es) 2005-08-26 2014-04-21 Merck Serono Sa Derivados de pirazina y su uso como inhibidores de PI3K
AU2006331917A1 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
CA2680778C (en) * 2007-03-20 2016-05-10 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
US20100240656A1 (en) 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
NZ594414A (en) 2009-01-16 2013-08-30 Curis Inc Fused amino pyridines for the treatment of brain tumors
KR101906568B1 (ko) 2009-10-07 2018-10-10 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 저해제로서 유용한 퓨린 유도체
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 grp94 저해제 및 이의 용도

Also Published As

Publication number Publication date
KR101984480B1 (ko) 2019-05-31
ES2647889T3 (es) 2017-12-27
CN103596955A (zh) 2014-02-19
US20140045867A1 (en) 2014-02-13
AU2012240079A1 (en) 2013-11-07
JP5961683B2 (ja) 2016-08-02
NZ616890A (en) 2016-01-29
CN103596955B (zh) 2016-11-16
JP2014510149A (ja) 2014-04-24
KR20140073464A (ko) 2014-06-16
WO2012138896A1 (en) 2012-10-11
CA2832099A1 (en) 2012-10-11
EP2694506B1 (en) 2017-09-20
AU2012240079B2 (en) 2017-05-18
CA2832099C (en) 2019-07-09
EP2694506A1 (en) 2014-02-12
MX2013011531A (es) 2014-08-22
US20170151247A1 (en) 2017-06-01
US10064867B2 (en) 2018-09-04
EA024647B1 (ru) 2016-10-31
US9546170B2 (en) 2017-01-17
MX354215B (es) 2018-02-19
EA201391337A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
SMT201500271B (it) Inibitori di neprilisina
CR20120576A (es) Inhibidores de pirazolil quinazolina cinasa
CO6900145A2 (es) Compuesto de ciclopropanoamina
BR112013025761A2 (pt) inibidores de hsp90
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112013010649A2 (pt) refrigerador
DK2769050T3 (da) Propsensor
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
DK3141251T3 (da) Koloskopi - forberedelse
DK2812341T3 (da) C-terminale hsp90-inhibitorer
DE112011104936A5 (de) Stanzstauchniet
DK2482015T3 (da) Køleskab
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 28/01/2020.